Pfizer’s $500M Breakthrough Growth Initiative Targets Innovative Biotechs – Could You Be Next?

If you lead a biotechnology company focused on internal medicine, inflammation, immunology, oncology, rare diseases, and vaccines, and believe your technology has the potential to disrupt the industry, here is some good news: Pfizer, a renowned pharmaceutical company, has $500 million available and is seeking to invest in such promising future stars.

Today, Pfizer announced the launch of the “Pfizer Breakthrough Growth Initiative,” committing up to $500 million in funding for investments in biotechnology companies to help them complete critical clinical development programs.

It is well known that new drug development is a protracted process, entailing substantial time and financial costs. Even with cutting-edge technology, companies may still face periods of funding gaps during research and development. In such circumstances, securing tens of millions of dollars in investment would be timely assistance, enabling small and mid-sized biotechnology firms to complete their final push.

▲Some companies that recently received investment from Pfizer (Data compilation/Graphic: WuXi AppTec Content Team)

In fact, according to data from the WuXi AppTec content team, Pfizer has been very active in investing in biotechnology companies recently. Just last month, it participated in Amplyx’s Series C financing round in San Diego, USA, bringing the total amount raised to $93 million. At the end of last year, Pfizer also led Triplet Therapeutics’ $59 million Series A financing round.

Pfizer’s past investments reveal that central nervous system (CNS) disorders were once a key area of interest. However, this field was not mentioned in the current initiative. The press release stated that the focus is on areas aligned with Pfizer’s primary R&D directions. Pfizer also noted in the press release that companies it invests in will have opportunities to collaborate with Pfizer experts in research and clinical development.

Some analyses also point out that Pfizer’s past investments were either concentrated in early-stage biotechnology companies or directly involved licensing agreements in the mid-to-late stages. This $500 million investment is expected to fill the gap in between, helping these biotechnology companies mature and complete the closed loop.

At present, Pfizer has not yet announced the specific timeline for its investment, nor is it clear how the $500 million will be allocated. If your biotechnology company operates in the relevant fields, please follow the “Chuangjianhui” WeChat official account and share this information with entrepreneurs around you. We will continue to provide updates on related financing and investment news and developments.

References:

[1] PFIZER ESTABLISHES NEW PROGRAM TO SUPPORT CONTINUED BIOTECHNOLOGY INNOVATION, Retrieved June 2, 2020, from https://www.pfizer.com/news/press-release/press-release-detail/pfizer-establishes-new-program-support-continued

[2] Pfizer’s Doug Giordano has $500M — and some advice — to offer a certain breed of 'breakthrough' biotech, Retrieved June 2, 2020, from https://endpts.com/pfizers-doug-giordano-has-500m-and-some-advice-to-offer-a-certain-breed-of-breakthrough-biotech/